IL22 and breast carcinoma: Given our current observations that both IL-22R1 and S1P1R expression is elevated in bone metastatic breast cancer (Figure 1), we investigated whether IL-22 stimulates the S1P signaling pathway in human bone marrow-derived mesenchymal stem cells (hBM-MSCs), which reside in the bone environment.